Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH), developed for research into its potential neuroactive and regulatory properties. Unlike full-length ACTH, Semax does not exhibit hormonal steroidogenic activity and has been studied primarily for its influence on central nervous system signaling pathways.

Preclinical research suggests that Semax may interact with neurotrophic and neurotransmitter-related pathways, including potential modulation of brain-derived neurotrophic factor (BDNF) expression and monoaminergic signaling. These mechanisms are believed to underlie its observed effects in experimental models examining cognitive processing, attention regulation, and adaptive stress responses. Researchers have also explored its potential role in supporting neural resilience and synaptic plasticity under controlled conditions.

Beyond cognitive-focused investigations, Semax has been studied for its possible influence on neuroprotective signaling and inflammatory balance within neural tissues. Ongoing research continues to evaluate its impact on neuroplasticity, central nervous system homeostasis, and adaptive physiological regulation.

‍